MRK: Sac-TMT Gets FDA Breakthrough Therapy Designation For EGFR-mutated Advanced Or ...
Merck & Co., Inc. (MRK) announced Tuesday that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to ...
Cure Today1 小时
FDA Grants Breakthrough Therapy Designation to Sac-TMT for Some with NSCLC
The FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for patients with advanced or metastatic ...
Merck Receives FDA Breakthrough Therapy Designation for Investigational Lung Cancer Treatment
Merck ( MRK, Financials) stated that sacituzumab tirumotecan (sac-TMT) was designated a Breakthrough Therapy by the FDA for advanced or metastatic nonsquamous non-small cell lung cancer with epidermal ...
Merck: FDA grants Breakthrough Therapy designation to sacituzumab tirumotecan
Merck (MRK) announced that the U.S. FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for the treatment of patients ...
marketinference1 小时
Janux Therapeutics Reports Positive Clinical Data
Janux Therapeutics' pipeline includes janx007, a tumor-activated T cell engager (TRACT) that targets prostate-specific ...
红板报 on MSN19 小时
再迎突破！复宏汉霖H药 汉斯状获批非鳞状非小细胞肺癌新适应症
2024年12月3日，上海——复宏汉霖（2696.HK）宣布，公司自主研发的创新型抗PD-1单抗H药 汉斯状（通用名：斯鲁利单抗注射液）正式获得国家药品监督管理局（NMPA）批准，联合培美曲塞和卡铂适用于表皮生长因子受体（EGFR）基因突变阴性和间变性淋巴瘤激酶（ALK）阴性的不可手术切除的局部晚期或转移性非鳞状非小细胞肺癌（nsNSCLC）的一线治疗。这是H药在中国获批的第五项适应症，也是继鳞状 ...